Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQ: IRWD · Real-Time Price · USD
4.890
+0.030 (0.62%)
At close: Jan 30, 2026, 4:00 PM EST
4.960
+0.070 (1.43%)
After-hours: Jan 30, 2026, 7:52 PM EST
Ironwood Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts that cover Ironwood Pharmaceuticals stock have a consensus rating of "Hold" and an average price target of $5.74, which forecasts a 17.38% increase in the stock price over the next year. The lowest target is $0.70 and the highest is $14.
Price Target: $5.74 (+17.38%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Ironwood Pharmaceuticals stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $3 → $5 | Hold | Maintains | $3 → $5 | +2.25% | Jan 5, 2026 |
| Citizens | Citizens | Hold → Buy Upgrades $8 | Hold → Buy | Upgrades | $8 | +63.60% | Jan 5, 2026 |
| Wells Fargo | Wells Fargo | Hold Maintains $1 → $3 | Hold | Maintains | $1 → $3 | -38.65% | Nov 11, 2025 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $7 → $1 | Buy → Hold | Downgrades | $7 → $1 | -79.55% | Apr 15, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $8 → $0.7 | Strong Buy → Hold | Downgrades | $8 → $0.7 | -85.69% | Apr 15, 2025 |
Financial Forecast
Revenue This Year
305.22M
from 351.41M
Decreased by -13.14%
Revenue Next Year
418.81M
from 305.22M
Increased by 37.22%
EPS This Year
0.29
from 0.01
Increased by 5,155.83%
EPS Next Year
0.82
from 0.29
Increased by 180.70%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 321.5M | 484.7M | ||||
| Avg | 305.2M | 418.8M | ||||
| Low | 289.6M | 304.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -8.5% | 58.8% | ||||
| Avg | -13.1% | 37.2% | ||||
| Low | -17.6% | -0.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.34 | 1.16 | ||||
| Avg | 0.29 | 0.82 | ||||
| Low | 0.25 | 0.49 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 5,974.9% | 297.3% | ||||
| Avg | 5,155.8% | 180.7% | ||||
| Low | 4,329.6% | 68.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.